60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
Investing.com - Citizens has reiterated its Market Perform rating on Adicet Bio Inc. (NASDAQ:ACET), according to a research note released Wednesday. The stock has fallen 12.4% in the past week and 41.6% over the past year, according to InvestingPro data.
The firm maintained its rating based on Adicet’s expected cash per share position at the end of the third quarter of 2026, viewing the stock as fairly valued at current levels. However, InvestingPro analysis suggests the stock may be undervalued at its current price of $0.60, with a strong current ratio of 5.62 indicating solid short-term liquidity.
Adicet recently reported its financial results for the third quarter of 2025, highlighting preliminary results from its ADI-001 program in lupus nephritis and systemic lupus erythematosus, along with guidance for expansion in the autoimmune disease space.
The company also provided updates on ADI-212, its gene-edited, armored CAR T therapy for oncology, with plans to enter clinical trials in the second quarter of 2026.
Citizens noted that Adicet raised $74.8 million in net proceeds in the fourth quarter of 2025, resulting in a pro forma cash position of $177.9 million, but remains on the sidelines pending longer follow-up data and results from a larger patient cohort.
In other recent news, Adicet Bio, Inc. reported promising initial safety and efficacy data from its ADI-001 therapy trial for autoimmune diseases. The trial involved seven patients with lupus nephritis and systemic lupus erythematosus, where all showed rapid and sustained reductions in disease activity scores. Notably, all five lupus nephritis patients improved renal function, with three achieving complete renal responses. Following these results, Guggenheim raised its price target for Adicet Bio to $8.00, maintaining a Buy rating. Additionally, Adicet Bio announced an $80 million stock offering priced at $1.00 per share, with the company expecting to raise the gross proceeds before expenses. Meanwhile, Citizens reiterated a Market Perform rating for Adicet Bio after the release of preliminary data for its ADI-001 therapy. In other developments, Genenta Science S.p.A. held its annual shareholders’ meeting, approving the 2024 financial statements and appointing Dr. Francesco Galimi to the board. The board appointments include a one-year term with an aggregate annual directors’ compensation of €105,000.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.